Immunogenicity of therapeutic recombinant immunotoxins

Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads

(2015) Regina S. Salvat et al.   BIOTECHNOLOGY AND BIOENGINEERING

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo

(2015) Ronit Mazor et al.   Cellular & Molecular Immunology

Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A

(2015) Ronit Mazor et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice

(2015) Michael L. Manning et al.   JOURNAL OF IMMUNOLOGY

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

(2015) R. Mazor et al.   MOLECULAR CANCER THERAPEUTICS

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E

(2015) Silvia Ratto-Kim et al.   PLoS One

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

(2014) M. Onda et al.   JOURNAL OF IMMUNOLOGY

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

(2014) Tapan K. Bera et al.   LEUKEMIA RESEARCH

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

(2014) K. Hollevoet et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

(2014) C. Alewine et al.   MOLECULAR CANCER THERAPEUTICS

Removing T-cell epitopes with computational protein design

(2014) C. King et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

(2014) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of Mesothelin in Tumor Progression and Targeted Therapy

(2013) Zhewei Tang et al.   Anti-Cancer Agents in Medicinal Chemistry

Shaping T Cell – B Cell Collaboration in the Response to Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 by Peptide Priming

(2013) N. Kalaya Steede et al.   PLoS One

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

(2012) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

(2011) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo

(2011) Leonard Moise et al.   CLINICAL IMMUNOLOGY

A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

(2011) John E. Weldon et al.   FEBS Journal

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

(2011) J. R. Cantor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

(2011) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen

(2010) C. Oseroff et al.   JOURNAL OF IMMUNOLOGY

A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice

(2010) Johanna K. Hansen et al.   JOURNAL OF IMMUNOTHERAPY

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

(2010) Frank R. Brennan et al.   mAbs

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆

(2009) Satoshi Nagata et al.   ADVANCED DRUG DELIVERY REVIEWS

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

(2009) Anne S. De Groot et al.   CLINICAL IMMUNOLOGY

Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies

(2009) Robert Kreitman   CURRENT PHARMACEUTICAL DESIGN

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

(2009) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin

(2009) Jeannick Cizeau et al.   JOURNAL OF IMMUNOTHERAPY

How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations

(2009) Eva-Maria Jahn et al.   New Biotechnology

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

(2008) J. E. Weldon et al.   BLOOD

Translational applications of antibody phage display

(2008) Don L. Siegel   IMMUNOLOGIC RESEARCH

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA